New immunotherapy to help fight cancer developed


Team Udayavani, Dec 11, 2017, 4:45 PM IST

Houston: A team led by an Indian-origin researcher has developed a novel cancer treatment that genetically engineers a patient’s immune system to attack cancer cells.

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T-cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel.

The study also reported measurable responses in 82 percent of patients and complete responses in 54 percent, researchers said. Fifty-six percent were alive at 15 months following therapy, with some remaining cancer-free two years post-treatment, they said.

“With the FDA’s recent approval of this therapy, we believe this is a major advance in the treatment of patients with relapsed or refractory large B-cell lymphoma and is likely to save or prolong lives of many patients,” said Sattva Neelapu, a professor at The University of Texas in the US.

“This study demonstrated that axi-cel provides remarkable improvement in outcomes over existing therapies for these patients who have no curative options,” said Neelapu, who led the study published in The New England Journal of Medicine.

The study, which began in April 2015, administered axi-cel to 108 patients who had failed prior chemotherapy and autologous stem cell transplantation. In some cases, the patients who had received chemotherapy were too far progressed to undergo stem cell transplantation and were placed on the trial following chemotherapy.

The patients’ T-cells were extracted through a process called leukapheresis and genetically re-engineered with CAR molecules that help T-cells attack cancer cells. The re-engineered T cells are infused back into the patient.

“This is the first FDA-approved gene therapy to treat adult lymphoma. Axi-cel consists of the patients’ own T cells that have been reprogrammed, and then re-infused to detect and destroy lymphoma,” said Frederick Locke from Moffitt Cancer Center in the US.

“Many patients’ lymphoma tumours melted away within a month. The long-term follow-up results of the ZUMA-1 trial show that axi-cel remissions can last years, and these are patients that did not respond to chemotherapy,” said Locke.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Like UP, bring BJP to power in Jharkhand to ‘bulldoze’ mafia: Yogi at Koderma poll rally

Govt asks Wikipedia why it should not be treated as publisher instead of intermediary

SC upholds validity of UP madrassa law, says it does not violate principle of secularism

Bantwal: Theft at Shree Mahalingeshwar temple

States not empowered to take over all private properties for distribution to serve common good: SC

Chhattisgarh NAN ‘scam’: FIR against 2 retired IAS officers, former AG

Davangere: MLA Basavantappa returns Rs 1.2 lakh left behind at shop

Related Articles More

Risk of abnormal blood fat levels increased by about 30 pc during pandemic, finds study

Attention problems could be ‘middleman’ between genetic risk for, experiencing psychosis: Study

Meeting WHO’s sodium recommendations could avert deaths from heart, kidney disease: Study

Meeting WHO’s sodium recommendations could avert deaths from heart, kidney disease: Study

Study finds loss of smell linked with inflammation in 140 conditions, could be early sign of disease

MUST WATCH

Gho Pooja in Deepavali Festival

Melukote Deepavali

Ganapathi Co-operative Society Ltd

Udayavani Chinnara Banna 2024

Annapoorna Aahar | Food Places In Mysore


Latest Additions

Like UP, bring BJP to power in Jharkhand to ‘bulldoze’ mafia: Yogi at Koderma poll rally

Govt asks Wikipedia why it should not be treated as publisher instead of intermediary

MUDA Case: K’taka HC adjourns hearing to November 26

SC upholds validity of UP madrassa law, says it does not violate principle of secularism

Union Minister H D Kumaraswamy booked for threatening police officer

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.